147 related articles for article (PubMed ID: 2686431)
21. Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections.
Cox CE
Am J Med; 1989 Nov; 87(5A):157S-159S. PubMed ID: 2686415
[No Abstract] [Full Text] [Related]
22. Comparative, double-blind study of intravenous ciprofloxacin and intravenous ceftazidime in serious infection.
Ramirez-Ronda CH; Saavedra S; Rivera-Vazquez CR
Am J Med; 1989 Nov; 87(5A):195S-197S. PubMed ID: 2686423
[No Abstract] [Full Text] [Related]
23. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections.
Ramirez-Ronda CH; Saavedra S; Rivera-Vázquez CR
Am J Med; 1987 Apr; 82(4A):220-3. PubMed ID: 3555040
[TBL] [Abstract][Full Text] [Related]
24. Ciprofloxacin versus ceftazidime in skin and soft tissue infections.
Thadepalli H; Mathai D; Chuah SK; Bansal MB
J Chemother; 1989 Feb; 1(1):30-4. PubMed ID: 2656929
[TBL] [Abstract][Full Text] [Related]
25. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections.
Khan FA; Basir R
Chest; 1989 Sep; 96(3):528-37. PubMed ID: 2670465
[TBL] [Abstract][Full Text] [Related]
26. Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime.
Parish LC; Asper R
Am J Med; 1987 Apr; 82(4A):227-9. PubMed ID: 3555041
[TBL] [Abstract][Full Text] [Related]
27. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
28. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
[TBL] [Abstract][Full Text] [Related]
29. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections.
Trenholme GM; Schmitt BA; Spear J; Gvazdinskas LC; Levin S
Am J Med; 1989 Nov; 87(5A):116S-118S. PubMed ID: 2686411
[TBL] [Abstract][Full Text] [Related]
30. Clinical experience with ciprofloxacin.
Palmer JP; Barit MC; Powderly B; Velasquez BG
W V Med J; 1989 Jul; 85(7):280-2. PubMed ID: 2667259
[TBL] [Abstract][Full Text] [Related]
31. Safety of cefepime: a new extended-spectrum parenteral cephalosporin.
Neu HC
Am J Med; 1996 Jun; 100(6A):68S-75S. PubMed ID: 8678100
[TBL] [Abstract][Full Text] [Related]
32. Oral ciprofloxacin in resistant urinary tract infections.
Ryan JL; Berenson CS; Greco TP; Mangi RJ; Sims M; Thornton GF; Andriole VT
Am J Med; 1987 Apr; 82(4A):303-6. PubMed ID: 3555052
[TBL] [Abstract][Full Text] [Related]
33. Ciprofloxacin: an update on clinical experience.
Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
[TBL] [Abstract][Full Text] [Related]
34. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of the safety profile of oral and intravenous ciprofloxacin in a geriatric population.
Heyd A; Haverstock D
Clin Ther; 2000 Oct; 22(10):1239-50. PubMed ID: 11110234
[TBL] [Abstract][Full Text] [Related]
36. Intravenous or sequential ciprofloxacin therapy in hospitalised patients with a broad spectrum of infections: a post-marketing surveillance study.
Koch H; Landen H; Stauch K
Clin Drug Investig; 2006; 26(11):645-54. PubMed ID: 17163299
[TBL] [Abstract][Full Text] [Related]
37. Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin.
Bouza E; Díaz-López MD; Bernaldo de Quirós JC; Rodríguez-Créixems M
Am J Med; 1989 Nov; 87(5A):228S-231S. PubMed ID: 2589366
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections.
Fass RJ
Am J Med; 1987 Apr; 82(4A):202-7. PubMed ID: 3555037
[TBL] [Abstract][Full Text] [Related]
39. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group.
Krumpe PE; Cohn S; Garreltes J; Ramirez J; Coulter H; Haverstock D; Echols R
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():117-28. PubMed ID: 10225582
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy of ciprofloxacin in the treatment of patients with respiratory tract infections in Japan.
Kobayashi H
Am J Med; 1987 Apr; 82(4A):169-73. PubMed ID: 3555031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
